113173
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
玉屏通窍（YPTQ）治疗变应性鼻炎的多靶点作用：一种恢复失调的调节性 T 细胞并增强上皮屏障完整性的中药
Authors Jiang Y , Chen H , Guo Y, Yao Z, Shi J, Shen S, Lai C, Dai L, Cao W, Li J
Received 13 October 2025
Accepted for publication 11 December 2025
Published 30 December 2025 Volume 2025:18 Pages 18229—18245
DOI https://doi.org/10.2147/JIR.S572876
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Cynthia Koziol-White
Yongquan Jiang,1,* Hao Chen,1,* Yanan Guo,1,* Zhuowei Yao,1 Jiali Shi,1 Silin Shen,1 Chenxing Lai,1 Li Dai,1,2 Wanxin Cao,1 Jiping Li1
1Department of Otolaryngology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, People’s Republic of China; 2Department of Otology and Skull Base Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wanxin Cao, Email wanxincao@126.com Jiping Li, Email entlijiping@163.com
Background: Allergic rhinitis (AR) is a prevalent chronic inflammatory disease characterized by immune dysregulation and epithelial barrier dysfunction. Conventional therapies are often limited by side effects and insufficient efficacy in addressing the underlying pathophysiology. To explore alternative approaches, this study investigated the potential of YuPingTongQiao (YPTQ), a novel Traditional Chinese Medicine (TCM) formulation, as a multi-target treatment for AR.
Methods: An ovalbumin-induced AR rat model was established. Nasal allergic symptoms were assessed using a standardized scoring system. Histopathology, FC, RT-qPCR, and ELISA were performed to assess epithelial integrity, cell infiltration, cytokine expression, and immune cell phenotypes.
Results: YPTQ significantly alleviated AR symptoms, including nasal rubbing, sneezing, and rhinorrhea, in a dose-dependent manner. The high-dose YPTQ (YPTQ-H) group demonstrated superior efficacy compared to Loratadine. Mechanistically, YPTQ suppressed TH 2 cytokines (IL-4, IL-5, IL-13) and IL-33, restored follicular regulatory T (TFR) cell balance, and increased CTLA4 expression, thus mitigating IgE-mediated immune responses. Additionally, YPTQ enhanced epithelial barrier integrity by upregulating Claudin1 and reduced mucus hypersecretion by suppressing MUC2 expression. Histological analysis revealed decreased infiltration of eosinophils, mast cells, and goblet cells in the nasal mucosa.
Conclusion: YPTQ offers a safe, effective, and multi-target therapeutic option for AR, addressing both immune dysregulation and epithelial dysfunction. Its superior efficacy compared to Loratadine and excellent safety profile highlight its potential as a novel alternative or adjunct to conventional treatments for AR.
Keywords: allergic rhinitis, traditional Chinese medicine, multi-target therapy
1Department of Otolaryngology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, People’s Republic of China; 2Department of Otology and Skull Base Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wanxin Cao, Email wanxincao@126.com Jiping Li, Email entlijiping@163.com
Background: Allergic rhinitis (AR) is a prevalent chronic inflammatory disease characterized by immune dysregulation and epithelial barrier dysfunction. Conventional therapies are often limited by side effects and insufficient efficacy in addressing the underlying pathophysiology. To explore alternative approaches, this study investigated the potential of YuPingTongQiao (YPTQ), a novel Traditional Chinese Medicine (TCM) formulation, as a multi-target treatment for AR.
Methods: An ovalbumin-induced AR rat model was established. Nasal allergic symptoms were assessed using a standardized scoring system. Histopathology, FC, RT-qPCR, and ELISA were performed to assess epithelial integrity, cell infiltration, cytokine expression, and immune cell phenotypes.
Results: YPTQ significantly alleviated AR symptoms, including nasal rubbing, sneezing, and rhinorrhea, in a dose-dependent manner. The high-dose YPTQ (YPTQ-H) group demonstrated superior efficacy compared to Loratadine. Mechanistically, YPTQ suppressed TH 2 cytokines (IL-4, IL-5, IL-13) and IL-33, restored follicular regulatory T (TFR) cell balance, and increased CTLA4 expression, thus mitigating IgE-mediated immune responses. Additionally, YPTQ enhanced epithelial barrier integrity by upregulating Claudin1 and reduced mucus hypersecretion by suppressing MUC2 expression. Histological analysis revealed decreased infiltration of eosinophils, mast cells, and goblet cells in the nasal mucosa.
Conclusion: YPTQ offers a safe, effective, and multi-target therapeutic option for AR, addressing both immune dysregulation and epithelial dysfunction. Its superior efficacy compared to Loratadine and excellent safety profile highlight its potential as a novel alternative or adjunct to conventional treatments for AR.
Keywords: allergic rhinitis, traditional Chinese medicine, multi-target therapy